Innovator’s Pitch Challenge

Interested in Connecting? Please contact:
Jeff Liter
President & CEO 

Message the company or request a 1:1 meeting here

Company Description

Luminary is a clinical cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell dysfunction. Our novel ligand-based CAR designed to bind three targets is set to enter the clinic in Q3-2022. Luminary was founded by the team from B-MoGen that achieved a successful 5X exit in only three years. We are seeking Series A financing with venture firms or strategic partners to support our 1st clinical trial and development of our disruptive U-Receptor that can modulate antigen specificity. A quick video link on Luminary can be found at

Pitch Deck

Executive Summary